Tag: Therapeutics
Bone Therapeutics Introduces Interim Analysis in Phase IIb ALLOB Study
By Arnaud Bives Published on 07/15/2022 at 07:55 (Boursier.com) — Bone…
Checkpoint Therapeutics, Inc.: Wedbush for purchase
Marketzone with MT Newswires 2022 All the news about CHECKPOINT THERAPEUTICS, INC. Analyst Recommendations for CHECKPOINT THERAPEUTICS, INC. 2022…
Checkpoint Therapeutics, Inc.: Wedbush still on the buy
Marketzone with MT Newswires 2022 All the news about CHECKPOINT THERAPEUTICS, INC. Analyst Recommendations for CHECKPOINT THERAPEUTICS, INC. 2022…
Biophytis provides an update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit Results of the COVA phase 2-3 study expected in the 3rd quarter of 2022 – 07/04/2022 at 08:00
Paris, France, Cambridge (Massachusetts, USA), July 4, 2022 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a stage clinic specializing in…
ImCheck Therapeutics takes on a new generation of cancer drugs
In the Imcheck Therapeutics laboratories, in Marseille, on September 15, 2021. COPYRIGHT JEAN FONDACCI FOR IMCHECK THERAPEUTICS It’s a cliché of the pharmaceutical industry. While Big Pharma rakes in billions…
Fulcrum Therapeutics, Inc.: HC Wainwright Maintains Buy Recommendation
Marketzone with MT Newswires 2022 All the news about FULCRUM THERAPEUTICS, INC. Analyst Recommendations on FULCRUM THERAPEUTICS, INC. 2022…
Bristol-Myers buys Turning Point Therapeutics for $4.1 billion
By Jean-Noel Legalland Published on 06/03/2022 at 1:38 p.m. Photo credit © Reuters …
A penny stock plummets: Relief Therapeutics crashes
As global stock markets rally, Relief Therapeutics’ stock price plummets. Inflation, the Ukraine war and other factors continue to weigh on stock market prospects. On the global stock markets, the…
Silverback Therapeutics, Inc.: Stifel Nicolaus Confirms Neutral Recommendation
Marketzone with MT Newswires 2022 All the news about SILVERBACK THERAPEUTICS, INC. Analyst Recommendations for SILVERBACK THERAPEUTICS, INC. 2022…
in a gloomy climate, Domain Therapeutics raises 39 million euros to fight cancer
A laboratory of the biotech Domain Therapeutics, in 2019. LUC BARON Treefrog, DNA Script, Mnemo, Pixium, Dental Monitoring… After a year 2021 marked by several record fundraisings in the French…
Akebia Therapeutics, Inc.: BTIG from long to neutral on the stock
Marketzone with MT Newswires 2022 All the news about AKEBIA THERAPEUTICS, INC. Analyst Recommendations on AKEBIA THERAPEUTICS, INC. 2022…
Notice of Knight Therapeutics’ Fourth Quarter and Year-End 2021 Results Conference Call
MONTREAL, March 17, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-EU) specialty pharmaceutical company, will release its fourth quarter and year-end 2021 financial results…